Hormonal Dependence of Benign Breast Disease, Gynecomastia and Breast Cancer

  • B. de Lignières
  • P. Mauvais-Jarvis


Until recently, the hormone dependence of the human mammary gland appeared unclear. In 1979, conflicting interpretations were still published on the essential physiological and pathological points (Diamont and Hollander, 1979). These contradictions have several origins: until a short time ago, women with breast diseases were exclusively seen by surgeons, radiologists and cancerologists and there were few possibilities of endocrinological investigation. Only the recent epidemiological enquiries draw attention to certain characteristics of genital life, and, above all, the use of various estro-progestative drugs for contraception or treatment of menopause lead to seeking advice from an endocrinologist.


Breast Cancer Breast Disease Benign Breast Disease Human Species Plasma Estradiol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Antoniades, K., and Spector, H., 1979, Correlation of estrogen receptor levels with histology and cytomorphology in human mammary cancer. Am. J. Clin. Path., 71, 497–503.PubMedGoogle Scholar
  2. Antunes, C.M.F., Stolley, P.D., Rosenshein, N.B., Davies, J.L., Tonascia, J.A., Brown, C., Burnett, L., Rutledge, A., Pokempner, M., and Garcia, R., 1979, Endometrial cancer and estrogen use. N. Engl. J. Med., 300, 9–13.PubMedCrossRefGoogle Scholar
  3. Backstrom, T., and Carstensen, H., 1974, Estrogen and progesterone in plasma in relation to premenstrual tension. J. Steroid Biochem., 5, 257–260.PubMedCrossRefGoogle Scholar
  4. Baldwin, R.L., and Plucinski, T., 1977, Mammary gland development and lactation. In “Reproduction in domestic animals”. H.M. Cole and P.T. Cupps, Eds., Academic Press, New York, p 369.Google Scholar
  5. Bishop, H.M., Blarney, R.W., Elston, C.W., and Haybittle, J.L., 1979, Relationship of oestrogen receptor status to survival in breast cancer. Lancet, 1, 283–284.CrossRefGoogle Scholar
  6. Black, M.M., Barclay, T.H.C., Cutler, S.J., Hankey, B.F., and Asire, A.J., Association of typical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer, 29, 338–343.Google Scholar
  7. De Boever, J., Desmet, B., and Vandekerckhove, D., 1980, Variation of progesterone, 20α-dihydroprogesterone and estradiol concentration in human mammary tissue and blood after topical administration of progesterone in “Percutaneous administration of steroids”. Mauvais-Jarvis P., Vichers C.F.H., Wepierre J., Eds., Academic Press, New York, in Press.Google Scholar
  8. Bulbrook, R.D., Moore, J.W., Clark, G.M.G., Wang, D.Y., Tong, D., and Hayward, J.L., 1978, Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer. Europ. J. Cancer, 14, 1369–1375.CrossRefGoogle Scholar
  9. Cardiff, R.D., Wellings, S.R., and Faulkin, L.J., 1977, Biology of breast preneoplasia. Cancer, 39, 2734–2746.PubMedCrossRefGoogle Scholar
  10. Cecil, H.C., Hannum, J.A., and Bitman, J., 1966, Quantitative characterization of uterine vascular permeability changes with estrogen. Am. J. Physiol., 211, 1099–1102.PubMedGoogle Scholar
  11. Colin, C., Gaspard, U., and Lambotte, R., 1978, Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with Lynestrenol. Arch. Gynäk., 225, 7–13.CrossRefGoogle Scholar
  12. MacCornack, F.A., Nathan, J.K., Covey, L.S., and Wynder, E.L., 1977, Oral contraceptive use. Epidemiology. New York State. J. Med., 77, 200–202.Google Scholar
  13. Cortes-Gallegos, V., Gallegos, A.J., Sanchez Basurto, C., and Rivadeneyra, J., 1975, Estrogen peripheral levels vs estrogen tissue concentration in the human female reproductive tract. J. Steroid. Biochem., 6, 15–20.PubMedCrossRefGoogle Scholar
  14. Corvol, P., Mahoudeau, J.A., Valcke, J.C., Menard, J., and Bricaire, H., 1976, Effets sexuels secondaires des spironolactones. Mécanismes possibles de l’action anti-androgène. Nouv. Presse Med., 5, 691–696.Google Scholar
  15. Dargent, D., Rivier, A., and Lasne, R., 1977, La fonction ovarienne des femmes atteintes de mastopathie non cancéreuse. Sénologia, 2, 11–17.Google Scholar
  16. Dasgupta, P.R., Ghosh, M., Pande, J.K., and Kar, A.B., 1970, Antiestrogenicity of norgestrel. Curr. Science, 39, 467–468.Google Scholar
  17. Desphande, N., Jensen, E.V., and Bulbrook, R.D., 1967, Accumulation of tritiated oestradiol by human breast tissue. Steroids, 10, 219–232.CrossRefGoogle Scholar
  18. Diamond, E.J., and Hollander, V.P., 1979, Progesterone and breast cancer. Mount Sinai J. Med., 46, 225–235.Google Scholar
  19. Donnelly, P.K., Baker, K.W., Carney, J.A., and O’Fallow, W.M., 1975, Benign breast lesions and subsequent breast carcinoma in Rochester, Minnesota. Mayo. Clin. Proc., 50, 650–656.PubMedGoogle Scholar
  20. Duperray, B., and Sitruk-Ware, R., 1979, Mammographie dynamique. Intérêt du traitement progestatif préalable. Nouv. Presse Méd., IB, 3058-3059.Google Scholar
  21. Editorial, 1979, What does prolactin do in man? Lancet, 1, 234–235.Google Scholar
  22. Ford, K., 1978, Contraceptive use in the United States, 1973–1976. Family Planning Perspectives, 10, 264–269.PubMedCrossRefGoogle Scholar
  23. Fournier, S., and Kuttenn, F., 1980, Estradiol and Progesterone receptors in breast fibroadenomas in women, in Press.Google Scholar
  24. Franks, S., and Brook, C.G.D., 1976, Basal and stimulated prolactin levels in childhood. Horm. Res., 7, 65–76.PubMedCrossRefGoogle Scholar
  25. Frantz, A.G., Kleinberg, D.L., and Noel, G.L., 1972, Studies on prolactin in man. Recent Prog. Horm. Res., 28, 527–573.PubMedGoogle Scholar
  26. Gairard, B., 1979, Profil hormonal dans les mastodynies. Rev. Med., 20, 477–480.Google Scholar
  27. Gambrell, R.D., 1978, The prevention of endometrial carcinoma in postmenopausal women with progestagens. Maturitas, 1, 107–112.PubMedCrossRefGoogle Scholar
  28. Gräf, K.J., and El Etreby, M.P., 1979, Endocrinology of reproduction in the female beagle dog and its significance in mammary gland tumorigenesis. Acta Endocrinol. Suppl 222, p 1–33.Google Scholar
  29. Gros, C., Gautherie, M., Bourjat, P., and Vrousos, C., 1969, Thermographie des affections mammaires. Radiol., 5, 68–81.Google Scholar
  30. McGuire, W.L., Zava, D.T., Horwitz, K.B., Garola, R.E., and Chamness, G.C., 1978, Receptors and breast cancer: do we know it all? J. Steroid Biochem., 9, 461–466.PubMedCrossRefGoogle Scholar
  31. Haagensen, C.D., 1971, Diseases of the breast. Saunders Co Edit. Philadelphia, p 159.Google Scholar
  32. Haagensen, C.D., 1977, The relationship of gross cystic disease of the breast and carcinoma. Ann. Surg., 185, 375–376.PubMedCrossRefGoogle Scholar
  33. Hammond, C.B., Jelovsek, F.R., Lee, K.L., Creasman, W.T., and Parker, R.T., 1979, Effects of long term estrogen replacement therapy. II. Neoplasia. Am. J. Obstet. Gynecol., 133, 537–547.Google Scholar
  34. Hoover, R., Gray, L.A., Cole, P., and MacMahon, B., 1976, Menopausal estrogens and breast cancer. New Engl. J. Med., 295, 401–405.PubMedCrossRefGoogle Scholar
  35. Huseby, R.A., and Thomas, L.B., 1954, Histological and histochemical alterations in the normal breast tissues of patients with advanced breast cancer being treated with estrogenic hormones. Cancer, 7, 54–74.PubMedCrossRefGoogle Scholar
  36. Keifer, W.S., and Scott, J.C., 1975, A clinical appraisal of patients following long term contraception. Am. J. Obstet. Gynecol., 122, 446–458.PubMedGoogle Scholar
  37. Kodlin, D., Winger, E.E., Morgenstern, N.L., and Chen, U., 1977, Chronic mastopathy on breast cancer. A follow-up study. Cancer, 39, 2603–2607.Google Scholar
  38. Lafaye, C., and Aubert, B., 1978, Action de la progesterone locale dans les mastopathies bénignes. J. Gyn. Obst. Biol. Repr., 7, 1123–1139.Google Scholar
  39. Large, D.M., and Anderson, D.C., 1979, Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynecomastia. Clin. Endocrinol., 11, 505–521.CrossRefGoogle Scholar
  40. Lee, P.A., 1975, The relationship of concentrations of serum hormones to pubertal gynecomastia. J. Pediatr., 86, 212–215.PubMedCrossRefGoogle Scholar
  41. Lee, P.A., Xenakis, T., Winer, J., and Matsenbaugh, S., 1976, Puberty in girls: correlation of serum levels of gonadotrophins, prolactin, androgens, estrogens and progestins with physical changes. J. Clin. Endocrinol., 43, 775–784.CrossRefGoogle Scholar
  42. Lees, A.W., Burns, P.E., and Grace, M., 1978, Oral contraceptives and breast disease in premenopausal nothern Albertan women. Int. J. Cancer, 22, 700–707.PubMedCrossRefGoogle Scholar
  43. Leung, B.S., and Sasaki, G.H., 1973, Prolactin and progesterone effect on specific estradiol binding in uterine and mammary tissues in vitro. Biochem. Biophys. Res. Comm., 55, 1180–1187.PubMedCrossRefGoogle Scholar
  44. Lignières, B. de, 1976, Cybernétique hormonale du sein: II pathologie. Sénologia, 1, 53–62.Google Scholar
  45. Lippman, M.E., Osborne, C.K., Knazek, R., and Young, N., 1977, In vitro model systems for the study of hormone dependent human breast cancer. New Engl. J. Med., 296, 154–159.PubMedCrossRefGoogle Scholar
  46. MacMahon, B., Cole, P.C., and Brown, J., 1973, Etiology of human breast cancer: a review. J. Nat. Cancer Inst., 50, 21–42.PubMedGoogle Scholar
  47. Martin, P.M., Kuttenn, F., Serment, H., and Mauvais-Jarvis, P., 1978, Studies on clinical, hormonal and pathological correlations in breast fibroadenoma. J. Steroid. Biochem., 9, 1251–1255.PubMedCrossRefGoogle Scholar
  48. Mauvais-Jarvis, P., and Kuttenn, F., 1975, L’insuffisance en progesterone est-elle cancérigène? Nouv. Presse Med., 4, 323–326.PubMedGoogle Scholar
  49. Mauvais-Jarvis, P., Sterkers, N., Kuttenn, F., and Beauvais, J., 1978, Traitement des mastopathies bénignes par la progesterone et les progestatifs. Résultats en fonction du type de mastopathie. J. Gyn. Obst. Biol. Repr., 7, 477–484.Google Scholar
  50. Mauvais-Jarvis, P., Tamborini, A., Sterkers, N., Ohlgiesser, G., and Mowszowicz, I., 1975, La fonction hormonale du corps jaune ovarien au cours des affections mammaires bénignes. J. Gyn. Obst. Reprod., 4, 965–970.Google Scholar
  51. May-Levin, F., Contesso, G., Guerinot, F., Delarue, J.C., and Bohuon, C., 1977, Récepteurs des estrogènes et de la progesterone dans les affections non carcinomateuses du sein. Path. Biol., 25, 233–239.Google Scholar
  52. Milligan, D., Drife, J.O., and Short, R.V., 1975, Changes in breast volume during normal menstrual cycle and after oral contraceptives. Brit. Med. J., 4, 494–496.PubMedCrossRefGoogle Scholar
  53. Monson, P.M., Yen, S., MacMahon, B., and Warren, S., 1976, Chronic mastitis and carcinoma of the breast. Lancet, 1, 224.CrossRefGoogle Scholar
  54. Morton, J.H., 1950, Premenstrual tension. Am. J. Obst. Gynec., 60, 343.Google Scholar
  55. Nagasawa, H., and Yanai, R., 1970, Effects of prolactin or growth hormone on growth of carcinogen-induced mammary tumors of adreno-ovariectomized rats. Int. J. Cancer, 6, 488–495.PubMedCrossRefGoogle Scholar
  56. Nagel, T.C., Freinkel, N., Bell, R.M., Friesen, H., Wilber, J.F., and Metzger, B.E., 1973, Gynecomastia, prolactin and other peptide hormones in patients undergoing chronic hemodialysis. J. Clin. Endocrinol. Metab., 36, 428.PubMedCrossRefGoogle Scholar
  57. Nassar, A.M., and Smith, R.E., 1975, Menstrual variations in thermal properties of the human breast. J. Appl. Physiol., 39, 806–811.PubMedGoogle Scholar
  58. Newsome, J.F., Timmons, R.L., Van Wyck, J., and Dugger, G.S., 1971, Pituitary stalk section for metastatic carcinoma of the breast. Ann. Surg., 174, 769–773.PubMedCrossRefGoogle Scholar
  59. Nimrod, A., and Ryan, K.J., 1975, Aromatization of androgens by human abdominal and breast fat tissue. J. Clin. Endocrinol. Metab., 40, 367–372.PubMedCrossRefGoogle Scholar
  60. Nomura, A., and Comstock, G.W., 1976, Benign breast tumor and estrogen hormones: a population based retrospective study. Am. J. Epidemiol., 103, 439–444.PubMedGoogle Scholar
  61. Paffenbarger, R.S., Fasal, E., Simmons, M.E., and Kampert, J.B., 1977, Cancer risk as related to use of oral contraceptives during fertile years. Cancer, 39, 1887–1891.PubMedCrossRefGoogle Scholar
  62. Pearson, O.K., and Manni, A., 1978, Hormonal control of breast growth in women and rats. Curr. Top. Exper. Endocrinol., 3, 75–92.Google Scholar
  63. Peck, D.R., and Lowman, R.M., 1978, Estrogen and the postmenopausal breast. J.A.M.A., 420, 1733–1735. 1733-1735.CrossRefGoogle Scholar
  64. Plata, E.J., Aoki, T., Robertson, D.D., Chu, E.W., and Gerwin, B.I., 1973, An established cultured cell line (HBT-39) from human breast carcinoma. J. Natl. Cancer Inst., 50, 849–862.PubMedGoogle Scholar
  65. Rajendran, K.G., Shah, P.N., Bagli, N.P., Mistry, S.S., and Ghosh, S.N., 1975, Steroid biosynthetic potential of gynaecomastic tissue in man. Horm. Res., 6, 329–335.PubMedCrossRefGoogle Scholar
  66. Royal College of General Practitioners, 1977, Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet, 1, 624.Google Scholar
  67. Saez, S., Martin, P.M., and Chouvet, C.D., 1978, Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res., 38, 3468–3473.PubMedGoogle Scholar
  68. Sherman, B.M., and Korenman, S.G., 1974, Inadequate corpus luteum function: a pathophysiological interpretation of human breast cancer epidemiology. Cancer, 33, 1306–1312.PubMedCrossRefGoogle Scholar
  69. Sitruk-Ware, R., Seradour, B., and Lafaye, C., 1980, Treatment of benign breast diseases by progesterone topically applied. In “Percutaneous absorption of steroids”. Mauvais-Jarvis P., Vichers C.F.H., Wepierre J. Eds., Academic Press, New York, in Press.Google Scholar
  70. Sitruk-Ware, L.P., Sterkers, N., Mowszowicz I., and Mauvais-Jarvis, P., 1977, Inadequate corpus luteal function in women with benign breast diseases. J. Clin. Endocrinol. Metab., 44, 771–774.PubMedCrossRefGoogle Scholar
  71. Sturder, D.W., Wade-Evans, T., Paterson, M.E.L., Thorn, M., and Studd, J.W.W., 1978, Relations between bleeding pattern, endometrial histology, and estrogen treatment in menopausal women. Brit. Med. J., 1, 1575–1577.CrossRefGoogle Scholar
  72. Thibault, C., and Levasseur, M.C., 1979, in “La fonction ovarienne chez les mammifères”. I.N.R.A. and Masson, Paris, p 57.Google Scholar
  73. Thorn, M.H., White, P.J., Williams, R.M., Sturdee, D.W., Paterson, M.E.L., Wade-Evans, T., and Studd, J.W.W., 1979, Prevention and treatment of endometrial disease in climacteric women receiving estrogen therapy. Lancet, 1, 455–457.Google Scholar
  74. Thorner, M.O., Round, J., Jones, A., Fahmy, D., Groom, G.V., Butcher, S., and Thomson, K., 1977, Serum prolactin and estradiol levels at different stages of puberty. Clin. Endocr., 7, 463–468.PubMedCrossRefGoogle Scholar
  75. Tseng, L., and Gurpide, E., 1975, Effects of progestins on estradiol receptor levels in human endometrium. J. Clin. Endocrinol. Metab., 41, 402–404.PubMedCrossRefGoogle Scholar
  76. Turkington, R.W., Underwood, L.E., and Van Wyk, J., 1971, Elevated serum prolactin after pituitary stalk section in man. New Engl. J. Med, 285, 707–710.PubMedCrossRefGoogle Scholar
  77. Vandaele, W., 1977, Progrès récents dans la connaissance du cycle sexuel des chiennes. Précautions à prendre lors de l’emploi de progestogènes. Ann. Med. Vet., 121, 369–381.Google Scholar
  78. Varela, R.M., and Dao, T.L., 1978, Estrogen synthesis and estradiol binding by human mammary tumors. Cancer Res., 38, 2429–2433.PubMedGoogle Scholar
  79. Vignon, F., and Rochefort, H., 1974, Regulation des récepteurs des estrogènes dans les tumeurs mammaires: effet de la prolactine in vivo. C.R. Acad. Sc. Paris, 278, 103–106.Google Scholar
  80. Warren, S., 1940, The relation of “chronic mastitis” to carcinoma of the breast. Surg. Gynecol. Obstet., 71, 257–273.Google Scholar
  81. Watson, G.H., Korach, K.S., and Muldoon, T., 1977, Obstruction of estrogen-receptor complex formation. Further analysis of the nature and steroidal specificity of the effect. Endocrinology, 101, 1733–1743.Google Scholar
  82. Weems-Chihal, H.J., Peppier, R.D., and Dickey, R.P., 1975, Estrogen potency of oral contraceptive pills. Am. J. Obstet. Gynecol., 121, 75–81.Google Scholar
  83. Wellings, S.R., Jensen, H.M., and Marcum, R.G., 1975, An atlas of subgross pathology of the human breast with special reference to precancerous lesions. J. Nat. Cancer Inst., 55, 231–273.PubMedGoogle Scholar
  84. Whitehead, M.I., McQueen, J., Minardi, J., and Campbell, S., 1978, Clinical considerations in the management of the menopause: the endometrium. Postgrad. Med. J., 54, suppl. 2, 69–73.PubMedGoogle Scholar
  85. Widholm, O., Kantero, R.L., Ascelson, E., Johansson, E.D.B., and Wide, L., 1974, Endocrine changes before and after the menarche. Urinary excretion of estrogen, FSK and LH, and serum levels of progesterone FSH and LH. Acta Obstet. Gynec, 53, 197–208.CrossRefGoogle Scholar
  86. Winters, J.S., and Faiman, C., 1973, The development of cyclic pituitary gonadal function in adolescent females. J. Clin. Endocrinol. Metab., 37, 714–718.CrossRefGoogle Scholar
  87. Winters, S.J., Banks, J.L., and Loriaux, D.L., 1979, The histamine H2-antagonist cimetidine is an antiandrogen. Gastroenterology, 76, 504–508.PubMedGoogle Scholar
  88. Wong, W.H., Freedman, R.I., Levan, N.E., Hyman, C., and Quilligan, E.J., 1972, Changes in the capillary filtration coefficient of cutaneous vessels in women with premenstrual tension. Am. J. Obstet. Gynecol., 114, 950–953.PubMedGoogle Scholar
  89. Zeppa, R., 1969, Vascular response of the breast to estrogen. J. Clin. Endocr., 29, 695–700.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • B. de Lignières
    • 1
  • P. Mauvais-Jarvis
    • 1
  1. 1.C.H.U. Necker-Enfants-MaladesParis Cédex 15France

Personalised recommendations